Insights

Innovation in Oncology Ellipses Pharma is focused on developing innovative cancer treatments through clinical trials, supported by partnerships with leading academic institutions and Big Pharma, indicating a strong pipeline and potential for licensing, collaboration, or funding opportunities for pharmaceutical suppliers and research services.

Recent Strategic Partnerships The company's recent collaboration with Innolakebio to develop a first-in-class antibody drug conjugate highlights their openness to strategic licensing and co-development deals, presenting opportunities for suppliers and partners in bioconjugation and ADC manufacturing sectors.

Strong Financial Backing Ellipses has attracted multi-million-pound investments from notable investors like West Coast Capital, suggesting a stable financial foundation and potential for investor relationships, grant applications, or growth capital sourcing for related service providers.

Clinical Trial Focus With a commitment to streamlining the complex clinical trial process and running multiple oncology trials in parallel, there is an opportunity for clinical trial management organizations, CROs, and biotech technology providers to support their rapid development cycle.

Technological Capabilities The company's utilization of various digital tools and content management systems demonstrates a tech-savvy approach, opening doors for innovation partnerships in digital CRO solutions, data management, and patient engagement platforms.

Ellipses Pharma Tech Stack

Ellipses Pharma uses 8 technology products and services including Hotjar, cdnjs, Open Graph, and more. Explore Ellipses Pharma's tech stack below.

  • Hotjar
    Analytics
  • cdnjs
    Content Delivery Network
  • Open Graph
    Content Management System
  • Slider Revolution
    Miscellaneous
  • DocuSign
    Miscellaneous
  • Google Tag Manager
    Tag Management
  • Nginx
    Web Servers
  • ContentViews
    Widgets

Media & News

Ellipses Pharma's Email Address Formats

Ellipses Pharma uses at least 1 format(s):
Ellipses Pharma Email FormatsExamplePercentage
First@ellipses.lifeJohn@ellipses.life
77%
FLast@ellipses.lifeJDoe@ellipses.life
14%
First.Last@ellipses.lifeJohn.Doe@ellipses.life
9%

Frequently Asked Questions

Where is Ellipses Pharma's headquarters located?

Minus sign iconPlus sign icon
Ellipses Pharma's main headquarters is located at 10 Stratton Street London, England w1j 8lg United Kingdom. The company has employees across 2 continents, including EuropeAsia.

What is Ellipses Pharma's official website and social media links?

Minus sign iconPlus sign icon
Ellipses Pharma's official website is ellipses.life and has social profiles on LinkedInCrunchbase.

What is Ellipses Pharma's SIC code NAICS code?

Minus sign iconPlus sign icon
Ellipses Pharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ellipses Pharma have currently?

Minus sign iconPlus sign icon
As of April 2026, Ellipses Pharma has approximately 39 employees across 2 continents, including EuropeAsia. Key team members include Cmo And Global Head Of Drug Development: T. A.Chief Business Development Officer: N. P.Chief Development Officer (cdo): Non Clinical: M. D.. Explore Ellipses Pharma's employee directory with LeadIQ.

What industry does Ellipses Pharma belong to?

Minus sign iconPlus sign icon
Ellipses Pharma operates in the Biotechnology Research industry.

What technology does Ellipses Pharma use?

Minus sign iconPlus sign icon
Ellipses Pharma's tech stack includes HotjarcdnjsOpen GraphSlider RevolutionDocuSignGoogle Tag ManagerNginxContentViews.

What is Ellipses Pharma's email format?

Minus sign iconPlus sign icon
Ellipses Pharma's email format typically follows the pattern of First@ellipses.life. Find more Ellipses Pharma email formats with LeadIQ.

Ellipses Pharma

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference.

Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities.  Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments.

Clinical trials are the route to developing more cancer treatments.   All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients.  We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective -  making more treatments available to patients.

Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel.  Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.

Section iconCompany Overview

Headquarters
10 Stratton Street London, England w1j 8lg United Kingdom
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Ellipses Pharma's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Ellipses Pharma's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.